Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Frontiers of Biomedical Science

Frontiers of Biomedical Science

Wednesday, October 19, 2005 - Thursday, October 20, 2005

Shanghai Institute for Biological Science

Presented By

Presented by the Chinese Academy of Sciences, Shanghai Institute for Biological Science and the New York Academy of Sciences


On October 19-20, 2005 eminent scientists from Europe, the US and China met to explore the most critical issues and research on the forefront of four cutting-edge disciplines:

  • Chemical Biology
  • Infectious Disease
  • Genomic Medicine
  • Neuroscience


Plenary lectures were combined with four concurrent interactive workshops attended by elite young Chinese scientists and international representatives from academia and industry.


  • Soren F. Andersen (Wyeth Research)
  • Emile-Etienne Baulieu (Cedex)
  • Jan Carlstedt-Duke (Karolinska Institute)
  • Zhu Chen (Chinese Academy of Sciences)
  • Virginia Cornish (Columbia University)
  • Peter B. Corr (Pfizer, Inc.)
  • Lin He (Shanghai Jiao-Tong University)
  • Hua-Liang Jiang (Shanghai Institute of Materia Medica, CAS)
  • Keith Jones (Affymetrix, Inc.)
  • Xiang-Yun Kong (Health Science Center, SIBS, CAS)
  • Bruce Lahn (Howard Hughes Medical Institute)
  • Chi-Ming Lee (AstraZeneca Pharmaceuticals LP)
  • Marc Lipsitch (Harvard School of Public Health)
  • Da-Wei Ma (Shanghai Institute of Organic Chemistry, CAS)
  • Jeremy Paul (New York Academy of Sciences)
  • David Perlin (Public Health Research Institute)
  • John Reid (AstraZeneca Pharmaceuticals LP)
  • Glenn Rice (Bridge Pharmaceuticals, Inc.)
  • Ellis Rubinstein (New York Academy of Sciences)
  • Joanna Rubinstein (Columbia University Medical School)
  • Bin Sun (Institute of Biochemistry and Cell Biology, SIBS, CAS)
  • Gregory Verdine (Harvard University)
  • Yi-Zheng Wang (Institute of Neuroscience, SIBS, CAS)
  • Jiarui Wu (Shanghai Institutes for Biological Science, CA)
  • Zheng-Hong Yuan (Fu-Dan University)
  • Xu Zhang (Institute of Neuroscience, SIBS, CA)


The meeting has been made possible with funding from

  • Alexandria Real Estate Equities
  • AstraZeneca
  • Pfizer
  • Affymetrix
  • Wyeth
  • Lundbeck
  • Bridge Pharmaceuticals
  • CMEA Ventures
  • Nature Publishing Group
  • The Karolinska Institute
  • PricewaterhouseCoopers.